Shanghai Bio-heart Biological

Shanghai Bio-heart Biological Technology Co., Ltd., along with its subsidiaries, researches, develops, and commercializes invasive treatment products in China. Its pipeline includes Bioheart, a bioresorbable scaffold system in registration stage for percutaneous coronary intervention in coronary artery disease; Iberis, a renal denervation system in clinical stage for uncontrolled and resistant hypertension; and DCB, a sirolimus drug-coated balloon catheter in clinical stage for in-stent restenosis. The company also provides local administration and manufacturing services. Founded in 2014, it is headquartered in Shanghai, China.